

DEUTSCHE BANK AG\

Form 3

October 23, 2008

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *

Â DEUTSCHE BANK AG\

(Last) (First) (Middle)

THEODOR-HEUSS-ALLEE 70

(Street)

60468 FRANKFURT AM MAIN

GERMAN,Â 2MÂ

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

04/08/2008

3. Issuer Name and Ticker or Trading Symbol

APEX BIOVENTURES ACQUISITION CORP [PEX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

____ Director ____X__ 10% Owner
____ Officer ____ Other
(give title below) (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)
__X__ Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)

2. Amount of Securities Beneficially Owned (Instr. 4)

3. Ownership Form:
Direct (D)
or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership (Instr. 5)

APEX BIOVENTURES ACQUISITION CORP

1,018,374

D Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

2. Date Exercisable and Expiration Date (Month/Day/Year)

Date Expiration
Exercisable Date

3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)

Title Amount or
Number of

4. Conversion or Exercise Price of Derivative Security

5. Ownership Form of Derivative Security: Direct (D)

6. Nature of Indirect Beneficial Ownership (Instr. 5)

| | | | | Shares | | | or Indirect (I) (Instr. 5) | |
|------------------------------------|------------|------------|--|---------|------|--|----------------------------------|---|
| APEX BIOVENTURES ACQUIS-CW11 | 06/07/2008 | 06/07/2011 | APEX BIOVENTURES ACQUISITION CORP | 203,514 | \$ 6 | | D | Â |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|---------|-------|
| | Director | 10% Owner | Officer | Other |
| DEUTSCHE BANK AG\ THEODOR-HEUSS-ALLEE 70 60468 FRANKFURT AM MAIN GERMANY, 2M | Â | Â X | Â | Â |

Signatures

Cesar A. Coy 10/23/2008

__Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.